Medline (NASDAQ:MDLN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Medline (NASDAQ:MDLN) had its target price hoisted by analysts at Royal Bank Of Canada from $47.00 to $53.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 11.56% from the company’s previous close.

MDLN has been the subject of a number of other reports. Bank of America initiated coverage on Medline in a report on Monday, January 12th. They issued a “buy” rating and a $50.00 price target for the company. BNP Paribas Exane began coverage on shares of Medline in a research note on Monday, January 12th. They set a “neutral” rating and a $38.00 target price for the company. Morgan Stanley began coverage on shares of Medline in a research report on Sunday, January 11th. They issued an “overweight” rating and a $48.00 price target on the stock. Citigroup began coverage on shares of Medline in a report on Monday, January 12th. They issued a “buy” rating and a $48.00 price target for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Medline in a research note on Monday, January 12th. They set a “buy” rating and a $49.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Medline has an average rating of “Moderate Buy” and an average price target of $50.35.

Medline Stock Down 2.8%

MDLN opened at $47.51 on Thursday. The business has a 50-day moving average of $44.52. Medline has a 1-year low of $34.89 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The company had revenue of $7.79 billion during the quarter, compared to analyst estimates of $7.52 billion. Medline’s quarterly revenue was up 14.8% compared to the same quarter last year.

Insider Transactions at Medline

In other news, Director Andrew J. Mills acquired 2,586,206 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director directly owned 2,586,206 shares in the company, valued at $74,999,974. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles N. Mills bought 2,579,310 shares of Medline stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the purchase, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Institutional Investors Weigh In On Medline

A number of hedge funds have recently made changes to their positions in the business. Carlyle Group Inc. acquired a new position in shares of Medline during the fourth quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. bought a new stake in Medline during the 4th quarter valued at $4,179,591,000. Vanguard Group Inc. acquired a new position in Medline during the 4th quarter worth $793,278,000. Morgan Stanley acquired a new position in Medline during the 4th quarter worth $636,807,000. Finally, Capital Research Global Investors bought a new position in shares of Medline in the fourth quarter worth $620,937,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.